METABOLISM OF ANTIEPILEPTIC DRUGS

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。这项研究试图利用一种稳定标记的卡马西平(CBZ)同位素静脉注射来表征年龄、性别和种族对卡马西平(CBZ)药代动力学和代谢的影响。这项研究还将试图确定CYP3A5*1等位基因纯合或杂合的受试者是否有更高的CBZ清除率和更快的消除半衰期。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study seeks to characterize the effects of advancing age, gender, and race on carbamazepine (CBZ) pharmacokinetics and metabolism utilizing an IV dose of a stable-labeled CBZ isotope. This study will also seek to determine if subjects homozygous or heterozygous for the CYP3A5*1 allele have an increased CBZ clearance and a faster elimination half-life.